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Abstract
Background: Migraine is a common neurovascular condition that may be linked to hyperhomocysteinemia. We
have previously provided evidence that reduction of homocysteine with a vitamin supplementation can reduce the
occurrence of migraine in women. The current study examined the occurrence of migraine in response to vitamin
supplementation with a lower dose of folic acid.
Methods: This was a 6 month randomised, double blinded placebo controlled trial of daily vitamin supplementation
containing 1 mg of folic acid, 25 mg of Vitamin B6 and Vitamin B12, on reduction of homocysteine and the occurrence
of migraine in 300 female patients diagnosed with migraine with aura.
Results: Vitamin supplementation with 1 mg of folic acid, did not significantly decrease homocysteine levels (P = 0.2).
The treatment group did not show a significant decrease in the percentage of participants with high migraine disability,
severity or frequency at the end of the 6 month intervention (P > 0.1).
Conclusion: 1 mg of folic acid in combination with vitamin B6 and B12 is less effective in reducing migraine associated
symptoms compared to the previously tested dosage of 2 mg folic acid in combination with 25 mg of vitamin B6 and
400 μg of vitamin B12.
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Background
Migraine is a very common episodic neurological dis-
order which is typically characterised by attacks of 4 to
72 h of severe headache and associated with autonomic
and neurological symptoms [1]. The International Head-
ache Society (IHS) has classified migraine into migraine
with aura (MA) and migraine without aura (MO) [2].
The incidence of migraine is much higher in females
(70 %) than in males (30 %) and is at its highest during
the peak reproductive years (between the ages of 25 and
55 years) [3]. Despite the high prevalence of migraine,
its pathophysiology is not completely understood. The
activation of the trigeminovascular system which results
in vasodilation of pain producing intracranial blood
vessels is thought to be responsible for the typical pain
migraineurs experience [4]. Family and twin studies have
shown that both common and rare migraine subtypes
have a significant genetic basis with environmental inter-
actions also playing an important role in disease manifest-
ation [1]. Previous studies have identified neurological,
vascular and hormonal pathways to be involved in mi-
graine susceptibility and pathophysiology [5, 6].
The human methylenetetrahydrofolate reductase
(MTHFR) gene is involved in the remethylation of homo-
cysteine to methionine. The C677T allele (rs1801133), a
common variant of the MTHFR gene has a frequency of
approximately 23–41 % in the Caucasian population [7].
The TT genotype of the MTHFR C677T SNP has been
shown to be associated with a 50 % reduction in enzyme
activity and consequently moderately increased levels of
circulating homocysteine [7–10]. This variant and elevated
homocysteine levels have been associated with the risk of
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several neurological conditions including migraine [11,
12]. Homocysteine related endothelial dysfunction might
be involved in the initiation and maintenance of a mi-
graine attack. Several studies have shown the TT genotype
of the MTHFRC677T variant to significantly increase the
risk of MA [8, 9].
Our laboratory has previously investigated the
homocysteine-lowering effects of vitamin supplemen-
tation in MA patients and the modifying effect of
C677T genotype on treatment response. In the Phase
1 trial, the effects of 2 mg folic acid, 25 mg vitamin
B6 and 400 μg vitamin B12 were examined in 52 MA
sufferers [13]. The major finding of this study was
that vitamin supplementation reduced plasma homo-
cysteine levels and migraine disability significantly in
this migraine group. This study also provided some
evidence that the effect of vitamin supplementation
on reduction of homocysteine levels and migraine dis-
ability was influenced by the MTHFRC677T genotype,
whereby carriers of the C allele experienced a greater
response compared to TT genotypes [13].
In the Phase 2 trial we replicated the treatment op-
tions in an independent and larger sample of MA suf-
ferers and examined the genotypic effects of both the
MTHFR and MTRR (5-Methyltetrahydrofolate-Homo-
cysteine Methyltransferase Reductase) gene on the re-
duction of homocysteine and migraine disability in
response to vitamin supplementation [14]. The Phase 2
trial provided further evidence that the MTHFR variant
influences treatment response and that the MTRR
variant may also be acting independently to influence
vitamin treatment response in migraineurs. Despite im-
provements in some participants, the more functionally
affected MTHFR T allele and MTRR G carriers seemed
to resist homocysteine reduction and did not respond as
well in terms of alleviation of migraine symptoms [14].
The purpose of this study was to determine if a lower
folic acid dosage (1 mg) that lies within the currently
recommended daily intake range was also effective in
reducing homocysteine levels and migraine disability.
This would enable the development of safe, persona-




The study recruited female Caucasian adult participants.
European descents living in Australia, having emigrating
ancestors within the last 160 years from various
locations within the British Isles and other parts of
Europe were recruited from East Coast of Australia
and were interviewed and completed a detailed ques-
tionnaire that was administered through the Genom-
ics Research Centre (GRC).
As migraine is more prevalent in females and this
prevalence reduces drastically in males only females be-
tween the ages of 18 and 60 were recruited. Participants
were included if they had suffered migraine for over >
5 years and had a current diagnosis of MA (>90 % of
their migraine attacks were associated with aura), and a
1-year history of severe, long lasting attacks (at least 4
attacks lasting more than 48 h), had a family history of
migraine. Confirmation of migraine diagnosis was car-
ried out using the IHS criteria. As this hypothesised that
the outcome variable, the response to vitamin therapy is
influenced by inherited factors, genetic independence of
participants was given important attention. Thus it was
made sure that only participants that are not related by
first degree were included in the study. Participants who
were currently taking vitamin supplementation, were
pregnant, or had been diagnosed with a clinically recog-
nised co-morbid disease such as vascular disease, depres-
sion or epilepsy were excluded from the trial to reduce
clinical and pathological heterogeneity. Participants that
had taken part in another clinical trial or had received any
experimental therapy within the last one month were also
excluded from the trial. The patient group was not se-
lected on the basis of pre-existing folic acid, B12 or B6 defi-
ciency. This study was originally approved by Griffith
University Human Research Ethics Committee (HREC),
approval number MSC/09/05/HREC.
Randomisation and blinding
Three hundred female patients meeting the inclusion
criteria were randomly assigned into either the placebo
or the treatment group. A blocked random allocation
sequence was generated using nQuery Advisor (Statis-
tical Solutions, Cork, [Ireland]). Patients and everyone
involved in this trial were blinded to randomisation and
group allocation. One hundred random female patients
were assigned to the placebo group and 200 random fe-
male patients were assigned to the vitamin tablet. The
numbers in the treatment group were higher to increase
the power for genotype comparisons in relation to treat-
ment response.
Treatment
Patients received either vitamin tablets containing 1 mg
of folic acid, 25 mg of vitamin B6 and 400 μg of vitamin
B12 or the placebo tablet. Both the vitamin and placebo
tablets were produced by Blackmores (Warriewood,
New South Wales, Australia) and were indistinguishable
in appearance. Patients were instructed to take one tab-
let daily for 6 months.
Baseline and follow-up assessment
Before the treatment all participants were assessed for mi-
graine disability using the Migraine Disability Assessment
Menon et al. The Journal of Headache and Pain  (2016) 17:60 Page 2 of 7
Score (MIDAS) instrument, which provides a measure of
productive days lost to migraine headache in previous
3 months (i.e. migraine disability), as well as headache fre-
quency and pain severity [13, 15]. Patients were asked to
complete a daily diary during the trial period to record the
details of their migraine symptoms (duration, frequency
and severity) and treatment compliance. Patients were
also instructed to take their usual migraine treatment for
acute attacks. A blood sample was collected for baseline
measurement of plasma homocysteine (μmol/l), folate
(nmol/l), vitamin B6 and B12 (pmol/l) concentration. 2 ml
of venous blood was collected for Genomic DNA extrac-
tion and genotyping purposes.
Patients were contacted after 3 months for headache
diary and compliance checking. At the end of the
6 month trial the patients were reassessed at the GRC
clinic. They were questioned about their migraine history
in the last 6 months since the start of the trial. A second
collection of blood samples was done for measurement of
homocysteine, folate, B6 and B12 concentrations.
Clinical outcome measures
Migraine disability measured by the MIDAS instrument
was the primary clinical outcome in this trial. Studies
have shown that the MIDAS instrument is a valid and
clinically useful instrument for assessing health-related
quality of life in migraineurs. Based on the 5-question
MIDAS rating, participants were arbitrarily categorised
into a ‘low’ disability group if they had a MIDAS rating
of 0–10 and into a ‘high’ disability group if they had a
MIDAS rating greater than 11 [13, 15, 16]. Secondary
outcome variables, which are partly captured within the
primary outcome, were migraine frequency and head
pain severity. These were measured as number of days
with headache (over a 3 month period) and a pain score
(based on a scale of 1–10), respectively [13, 15, 16].
Predictor variables
The primary predictor variable for this study was the
treatment groups (Vitamin vs placebo). The secondary
predictor variables include plasma homocysteine levels
and the C677T polymorphism of the MTHFR gene,
grouped by TT and CT and CC genotypes. The C677T
polymorphism was genotyped in the patient group in
the GRC laboratory using previously published methods
[9]. The Plasma homocysteine, folate, B6 and B12 levels
were measured in an accredited pathology laboratory
(TetraQ, University of Queensland, Brisbane) [17, 18].
Statistical analysis
The analysis for the trial was conducted on a modified
intention-to-treat (ITT) principle. The modified ITT co-
hort was composed of all randomised participants who
started the trial and consumed study supplements on at
least one occasion, excluding those who withdrew from
the trial after the randomisation process had taken place
but before the commencement of study supplement con-
sumption. At baseline and follow-up time points, un-
paired samples t-tests were used to test the group means
and proportions were compared using the χ2 test of in-
dependence. The significance threshold was set at α level
of 0.05. All analyses were performed using the Statistical
Package for Social Sciences (SPSS version 18.0; Inter-
national Business Machines, Chicago, Illinois, USA).
Results
Figure 1 shows the participant flow through the trial. A
total of 1050 migraineurs were assessed for eligibility be-
fore enrolment into the trial. Of them 750 migraineurs
were excluded because of reasons such as nonfulfillment
of the inclusion criterial, refusal to participate in a
placebo-controlled trial and other reasons. In total, 300
participants were initially enrolled in the trial and were
randomly assigned in the ration of 1:2 to either the pla-
cebo group or the vitamin- treated group respectively,
but seven participants dropped out before the com-
mencement of the trial and 36 participants dropped out
at baseline assessment. Two hundred and fifty seven par-
ticipants received baseline assessment and successfully
commenced trial. One hundred and seventy participants
were included in the vitamin- treated group and the
remaining 87 participants were included in the placebo-
treated group. Sixty eight participants were lost to
follow-up because of lack of compliance and 189 partici-
pants completed the trial (126 Vitamin treated, 63 Pla-
cebo treated).
Baseline analysis
Table 1 shows the baseline clinical characteristics of the
participant group. The mean folate concentration was
33.7 nmol/l and 35.6 nmol/l for the placebo and the
treatment group respectively, which were above the
average folate concentration of 13.7 nmol/l in the gen-
eral Caucasian population. The mean plasma homocyst-
eine concentration was 9.5 μmol/l and 9.4 μmol/l for the
placebo and the treatment group respectively, which
were slightly above the average plasma homocysteine
level of 8.9 μmol/l in the general Caucasian population.
The mean B6 and B12 levels at baseline for both the pla-
cebo and treatment groups were within the normal
range for a general Caucasian population. The percent-
age of participants with high migraine frequency and
high migraine severity did not significantly differ be-
tween the placebo and the treatment group at baseline,
however the percentage of participants with high mi-
graine disability significantly differed between the pla-
cebo and the treatment group (P =0.02). The placebo
group had an increased proportion of participants
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(91 %) with high migraine disability compared to the
treatment group (79 %).
Values are mean (SD) or n (%)
For the blood biochemistries at follow-up (Table 2) - fol-
ate, B6 and B12 levels were significantly higher in the
treatment group compared to placebo group (P < 0.0001)
after 6 months of intervention. Plasma homocysteine
levels remained at 9.5 μmol/l for the placebo group
while in the treatment group, plasma homocysteine
levels decreased from 9.4 to 8.5 μmol/l after the 6 months
of intervention. However this decrease was not statistically
significant (P = 0.2). This result is in contrast to our previ-
ous results testing the effect of 2 mg of folic acid, which
showed a statistically significant reduction in mean homo-
cysteine (P < 0.001) in the treatment group. The baseline
Hcy plasma levels of the treatment group was lower in the
current trial (9.4 μmol/l) compared to the previous trial,
this is most likely due to the higher level of baseline
folate levels in the current trial (35.6 nmol/l) com-
pared to the previous trial (31.4 nmol/l), which dis-
plays a possible floor effect.
For the migraine clinical outcomes at follow-up
(Table 3) the treatment group had a lower percentage of
participants with high migraine disability, severity and
frequency compared to the placebo group at the end of
the 6 month intervention. However, these differences
were not statistically significant (P > 0.1).
When the treatment group was stratified by the
MTHFR C677T genotype, an overall decrease in the per-
centage of high migraine disability, frequency and sever-
ity was observed for all three genotype groups after the
6 months of intervention however the decrease was not
statistically significant(P > 0.10).
Discussion
Migraine is a chronic and debilitating condition that has
significant impact on both the sufferer and the society at
large [19]. Although there are several migraine therapies
and medications currently available to treat migraine,
most of them work with differing efficacy and are often as-
sociated with adverse effects [20]. Migraine research thus
continues to explore new and/or improved migraine
Fig. 1 Patient flow chart of the trial
Table 1 Clinical characteristics of patient groups at baseline
Analyte Placebo (n = 87) 1 mg (n = 170)
Folate 33.7 (11.6) 35.6 (11.9)
B6 97.2 (7.3) 132.2 (12.1)
B12 266.1 (94.3) 289.3 (104.4)
Hcy 9.5 (2.6) 9.4 (2.8)
High Disability 79 (91 %) 134 (79 %)
High Frequency 56 (64 %) 109 (64 %)
High Severity 43 (49 %) 73(43 %)
Table 2 Summary of blood biochemistry measures at follow-up*
Analyte Placebo (n = 63) 1 mg (n = 126) P value*
Folate 34.6 (1.6) 52.6 (0.40) <0.0001
B6 134.6 (21.5) 490.6 (24.9) <0.0001
B12 274.1 (11.6) 456.8 (11.6) <0.0001
Hcy 9.5 (0.32) 8.5 (0.49) 0.2
Values are means (SEM)
Change in folate, B6,B12 and Hcy levels in the treatment and placebo group
after 6 months of intervention. Hcy levels did not significantly decrease in
the treatment group compared to the placebo group after 6 months of
intervention
*P values were determined by t-test
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treatments that are both effective and safe for use by all
migraineurs [21].
The Genomics Research Centre had previously tested
the effects of folate and vitamin B treatment response in
migraineurs in two previous studies [13, 14]. The results
of these previous studies and have reported the signifi-
cant decrease in migraine associated symptoms after a
6 month intervention of a vitamin tablet containing
2 mg folic acid, 25 mg of vitamin B6 and 400 μg of vita-
min B12 . When the effect of the MTHFRC677T and the
MTRR A66G genetic variants on migraine treatment
was assessed, it was observed that both these variants
exert an independent effect on migraine treatment re-
sponse [14].
The current trial investigated the effect of 1 mg folic
acid, 25 mg of vitamin B6 and 400 μg of vitamin B12 on
migraine associated symptoms on adult Caucasian fe-
males with MA. The aims of the current study was to
investigate the effectiveness of a vitamin supplementa-
tion incorporating 1 mg folic acid, 25 mg of vitamin B6
and 400 μg of vitamin B12 in significantly reducing mi-
graine associated symptoms and to investigate the effect
of the MTHFRC677T variant on the reduction of homo-
cysteine and migraine associated symptoms in response
to the vitamin supplementation.
The results of this trial did not observe a significant
reduction in homocysteine levels in the treatment group
compared to the placebo group (P = 0.2) and there was
also no significant decrease observed in migraine disabil-
ity, frequency or severity in treatment group compared
to the placebo group at the end of the treatment period.
This result was in contrast to the previous trials which
investigated vitamin supplementation of 2 mg folic acid,
25 mg of vitamin B6 and 400 μg of vitamin B12 and re-
ported significant decrease in homocysteine levels as
well as migraine associated symptoms compared to the
placebo group at the end of treatment period. Similarly
while the previous trial reported migraine associated var-
iants, in the MTHFR and MTRR genes to have a signifi-
cant effect on migraine treatment response, the current
trial did not observe any significant effect of the MTHFR
C677T gene variant on migraine treatment response.
This current study has provided evidence that the folic
acid dosage in the proposed vitamin supplementation
for migraine treatment plays a pertinent part in reducing
homocysteine levels and migraine associated symptoms.
Folate, a water-soluble vitamin, includes endogenous
food folate and its synthetic form, folic acid [22]. Folate
lacks stability in its naturally occurring form in food
storage and preparation; however, folic acid is stable and
used for supplements and food fortification [23]. There
are many critical cellular pathways dependent on folate
as a one-carbon source, including DNA, RNA, and pro-
tein methylation, as well as DNA synthesis and mainten-
ance [24]. A number of genetic polymorphisms affect
critical components of folate pathways and metabolism,
and have been associated with an increased risk for sev-
eral diseases [25–31]. Mandatory folate fortification of
wheat flour was implemented in Australia in 2009. The
tolerable upper intake level (UL) (1000 μg/day)of folic
acid was established as one-fifth of the lowest observed
adverse effect level (5000 μg/day) associated with a po-
tential adverse outcome [32]. Even at dosages of 15,000–
100,000 μg of folic acid daily, limited evidence was found
of direct toxicity from folic acid [33–38]. However re-
cently the possibility that folic acid intake might lead to
changes in epigenetic patterns and thus the plausible hy-
potheses of how folic acid might affect certain diseases
has led to concerns about higher folic acid intake and
food fortification programs.
The most important concern has surrounded cancer
as the field of epigenetics has been studied largely in the
context of tumorogenesis where clear DNA methylation
pattern changes in tumors have been reported [39–44].
It has been suggested that early exposure to folic acid
might prevent some cancers and in contrast, after the
development of tumors, higher intake of folic acid might
promote growth of existing tumors [45]. However, a very
recent meta-analysis of randomised clinical trials (RCTs)
of the effects of B vitamins on 37,485 individuals with
existing cardiovascular disease showed no increased risk
of cancer incidence. Additionally, since the implementa-
tion of mandatory folic acid fortification in the United
States in 1998, both incidence and mortality of colorectal
cancer have continued to decline [46]. With such varying
studies results, extensive research is warranted to fully
understand the effect of folic acid on disease risk.
Further research is thus needed to understand the use
of vitamin supplementation incorporating various doses
of folic acid, vitamin B6 and B12 in regards to not only
on the reduction of migraine associated symptoms but
also the long term effects of vitamin supplementation on
the general well-being of migraineurs.
Conclusion
The recommend dosage of 1 mg folic acid in combin-
ation with vitamins vitamin B6 and B12 is less effective in
Table 3 Summary of migraine outcomes at follow-up*
Analyte Placebo (n = 63) 1 mg (n = 126) P value*
(a) High Disability 34 (52 %) 56 (45 %) 0.4
(b) High Frequency 28 (43 %) 44 (36 %) 0.33
(c) High Severity 12 (19 %) 16 (13 %) 0.31
Values are n (%)
High disability (a) is defined as a MIDAS score >11, High Frequency (b) is
defined as a score >10 (median) and High Severity (c) is defined as a score >7
(median). All scores were categorised due to the deviation from non-normal
distribution and to improve interpretation
*P value were determined by Chi-square tests
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reducing migraine associated symptoms compared to
the previously tested dosage of 2 mg folic acid in
combination with 25 mg of vitamin B6 and 400 μg of
vitamin B12.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LG was involved in the conception and design of the study. SM and was
involved in the generation and collection of data. SM and NA were involved
in the genotyping of participant samples. MS and SG were involved in the
Biochemistry analysis of samples. SM and BN were involved in the assembly
of data. RL, SM and BN were involved in the analysis and interpretation of
the data. RL, SM and LG were involved in the drafting and revision of the
manuscript. LG, RL and CO were involved in approving the final version of
the manuscript. All authors have read and approved the final manuscript.
Acknowledgements
The authors acknowledge all the participants of this study who consented
and volunteered to participate in the trial.
Funding
This study was supported by funding from a Queensland (Qld) Government
Smart State CIF grant. The Genomics Research Centre is a member of the
Therapeutic Innovation Australia (TIA), QLD node with funding provided
through an ARC EIF Super Science Initiative, TIA NCRIS 2013 and TIA NCRIS
2015.
Author details
1Genomics Research Centre, Institute of Health and Biomedical Innovation,
Queensland University of Technology, Kelvin Grove, QLD, Australia. 2Centre
for Integrated Preclinical Drug Development Faculty of Medicine and
Biomedical Sciences, University of Queensland, Brisbane, QLD, Australia.
3Blackmores Institute, 20 Jubilee Avenue, Warriewood NSW 2102, Australia.
Received: 13 May 2016 Accepted: 17 June 2016
References
1. de Vries B et al (2009) Molecular genetics of migraine. Hum Genet 126(1):
115–32
2. (1994) Guidelines on the investigation and diagnosis of cobalamin and
folate deficiencies. A publication of the British Committee for Standards in
Haematology. BCSH General Haematology Test Force. Clin Lab Haematol.
16(2): 101–15
3. Stovner L et al (2007) The global burden of headache: a documentation of
headache prevalence and disability worldwide. Cephalalgia 27(3):193–210
4. Goadsby PJ et al (2009) Neurobiology of migraine. Neuroscience 161(2):
327–41
5. Cutrer FM (2010) Pathophysiology of migraine. Semin Neurol 30(2):120–30
6. Pietrobon D, Moskowitz MA (2013) Pathophysiology of migraine. Annu Rev
Physiol 75:365–91
7. Kara I et al (2003) Association of the C677T and A1298C polymorphisms in
the 5,10 methylenetetrahydrofolate reductase gene in patients with
migraine risk. Brain Res Mol Brain Res 111(1–2):84–90
8. Kowa H et al (2000) The homozygous C677T mutation in the
methylenetetrahydrofolate reductase gene is a genetic risk factor for
migraine. Am J Med Genet 96(6):762–4
9. Lea RA et al (2004) The methylenetetrahydrofolate reductase gene variant
C677T influences susceptibility to migraine with aura. BMC Med 2:3
10. Di Rosa G et al (2007) Efficacy of folic acid in children with migraine,
hyperhomocysteinemia and MTHFR polymorphisms. Headache 47(9):1342–4
11. Klerk M et al (2002) MTHFR 677C– > T polymorphism and risk of coronary
heart disease: a meta-analysis. JAMA 288(16):2023–31
12. Aguilar B, Rojas JC, Collados MT (2004) Metabolism of homocysteine and its
relationship with cardiovascular disease. J Thromb Thrombolysis 18(2):75–87
13. Lea R et al (2009) The effects of vitamin supplementation and MTHFR
(C677T) genotype on homocysteine-lowering and migraine disability.
Pharmacogenet Genomics 19(6):422–8
14. Menon S et al (2012) Genotypes of the MTHFR C677T and MTRR A66G
genes act independently to reduce migraine disability in response to
vitamin supplementation. Pharmacogenet Genomics 22(10):741–9
15. Stewart WF et al (1999) Validity of an illness severity measure for headache
in a population sample of migraine sufferers. Pain 79(2–3):291–301
16. Stewart WF et al (1999) Reliability of the migraine disability assessment
score in a population-based sample of headache sufferers. Cephalalgia
19(2):107–14, discussion 74
17. Ghassabian S et al (2014) Fully validated LC-MS/MS method for
quantification of homocysteine concentrations in samples of human serum:
a new approach. J Chromatogr B Analyt Technol Biomed Life Sci 972:14–21
18. Ghassabian S, Griffiths L, Smith MT (2015) A novel fully validated LC-MS/MS
method for quantification of pyridoxal-5’-phosphate concentrations in
samples of human whole blood. J Chromatogr B Analyt Technol Biomed
Life Sci 1000:77–83
19. Leonardi M et al (2005) The global burden of migraine: measuring disability
in headache disorders with WHO’s classification of functioning, disability
and health (ICF). J Headache Pain 6(6):429–40
20. Rapoport A (2011) New frontiers in headache therapy. Neurol Sci 32(Suppl
1):S105–9
21. Rainero I et al (2013) Genes and primary headaches: discovering new
potential therapeutic targets. J Headache Pain 14:61
22. Eitenmiller R, Landen W (1999) Vitamin analysis for the health and food
science. Folate., pp 411–465
23. O’Broin JD et al (1975) Nutritional stability of various naturally occurring
monoglutamate derivatives of folic acid. Am J Clin Nutr 28(5):438–44
24. Stover PJ (2009) Folate biochemical pathways and their regulation. In:
Folate in health and disease. Taylor & Francis Group, Gainesville, pp 49–74
25. Choi SW, Mason JB (2002) Folate status: effects on pathways of colorectal
carcinogenesis. J Nutr 132(8 Suppl):2413S–2418S
26. Bjelland I et al (2003) Folate, vitamin B12, homocysteine, and the MTHFR
677C- > T polymorphism in anxiety and depression: the hordaland
homocysteine study. Arch Gen Psychiatry 60(6):618–26
27. Perez AB et al (2003) Methylenetetrahydrofolate reductase (MTHFR):
incidence of mutations C677T and A1298C in Brazilian population and its
correlation with plasma homocysteine levels in spina bifida. Am J Med
Genet A 119A(1):20–5
28. Chango A et al (2005) No association between common polymorphisms in
genes of folate and homocysteine metabolism and the risk of Down’s
syndrome among French mothers. Br J Nutr 94(2):166–9
29. Alcasabas P et al (2008) 5,10-methylenetetrahydrofolate reductase (MTHFR)
polymorphisms and the risk of acute lymphoblastic leukemia (ALL) in
Filipino children. Pediatr Blood Cancer 51(2):178–82
30. Brustolin S, Giugliani R, Felix TM (2010) Genetics of homocysteine
metabolism and associated disorders. Braz J Med Biol Res 43(1):1–7
31. Sameer AS et al (2011) Risk of colorectal cancer associated with the
methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the
Kashmiri population. Genet Mol Res 10(2):1200–10
32. Insitute of Medicine, a., Dietary Reference Intakes for Thiamin, Riboflavin,
Niacin, Vitamin B6, Folate, Vitamin B12, Patothenic Acid, Biotin and Choline.,
in Folate. 1998, National Academy Press, Washington, p. 196–305
33. Spies TD, Suarez RM et al (1946) The therapeutic effect of folic acid in
tropical sprue. Science 104(2691):75
34. Gibberd FB et al (1970) Toxicity of folic acid. Lancet 1(7642):360–1
35. Hunter R et al (1970) Toxicity of folic acid given in pharmacological doses
to healthy volunteers. Lancet 1(7637):61–3
36. Hellstrom L (1971) Lack of toxicity of folic acid given in pharmacological
doses to healthy volunteers. Lancet 1(7689):59–61
37. Richens A (1971) Toxicity of folic acid. Lancet 1(7705):912
38. Sheehy TW (1973) Folic acid: lack of toxicity. Lancet 1(7793):37
39. Baylin SB (1997) Tying it all together: epigenetics, genetics, cell cycle, and
cancer. Science 277(5334):1948–9
40. Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis:
epigenetics joins genetics. Trends Genet 16(4):168–74
41. Momparler RL, Bovenzi V (2000) DNA methylation and cancer. J Cell Physiol
183(2):145–54
42. Feinberg AP (2001) Cancer epigenetics takes center stage. Proc Natl Acad
Sci U S A 98(2):392–4
43. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358(11):1148–59
44. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis
31(1):27–36
Menon et al. The Journal of Headache and Pain  (2016) 17:60 Page 6 of 7
45. Ciappio E, Mason JB (2009) Folate and carcinogenesis basis
mechanisms, in folate in health and disease. Taylor & Francis Group,
Boca Raton, pp 235–262
46. Edwards BK et al (2010) Annual report to the nation on the status of
cancer, 1975–2006, featuring colorectal cancer trends and impact of
interventions (risk factors, screening, and treatment) to reduce future
rates. Cancer 116(3):544–73
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Menon et al. The Journal of Headache and Pain  (2016) 17:60 Page 7 of 7
